Neural Terrain Protocol

Before any botanical: the glymphatic system — the brain's own waste-clearance network (Nedergaard et al.) — is active almost exclusively during deep sleep, when glial cells shrink and interstitial space expands up to 60% to let cerebrospinal fluid flush metabolic waste, including amyloid-beta. No supplement substitutes for this. Circadian disruption is a stronger predictor than sleep apnea alone: a large cohort of career night-shift workers showed HR 2.43 for dementia risk, versus HR 1.45 for diagnosed obstructive sleep apnea. Treat sleep apnea as one indicator of disrupted rhythm, not the only cause — undiagnosed shift-work history matters just as much. Room temperature has a real, measured effect, but it's a U-curve, not "colder is always better": 17–20°C supports deep sleep; below that, sleep quality drops again.

Restore blood-brain barrier integrity — but only in the form that's actually shown to reach neural tissue. Standard oral curcumin fails this test outright: no measurable brain-tissue concentration even at high IV doses. Intranasal or liposomal curcumin is the documented exception (17–79 nmol/g measured in cortex and olfactory bulb after intranasal dosing) — and within liposomal formulations, salmon-lecithin-based liposomes outperform rapeseed or soy lecithin for curcumin delivery specifically, since phospholipids are themselves a major structural component of neural tissue. Astaxanthin has been dropped from this step: no blood-brain-barrier data was found to support the earlier claim, and an unverified mechanism doesn't belong in a protocol built on the opposite standard.

Clear glycated protein waste, excess brain iron, and mercury from neural tissue itself — using only compounds with confirmed BBB penetration, not just systemic blood/urine markers. Carnosine occurs naturally in human brain tissue (0.1–1mM) and is the strongest AGE-clearance candidate on that basis alone. EGCG (green tea catechin) crosses the BBB at low concentration in human in-vitro models and reaches brain parenchyma. Ferulic and caffeic acid are BBB-permeable iron chelators in animal studies — a botanical parallel to deferiprone, the pharmaceutical iron chelator that (unlike deferoxamine) actually crosses the BBB — relevant given that brain iron accumulation appears to precede widespread amyloid/tau pathology. Chlorella is the one metal-clearance candidate with direct brain-tissue data: a mouse study showed reduced mercury concentration in brain tissue itself, not just urine or feces. Modified Citrus Pectin, used in earlier versions of this step, has been removed — its evidence is systemic only (urine excretion), with no indication it reaches neural tissue.

Suppress microglial overactivation — the neuroinflammatory cascade driven by NF-κB, TNF-α, and IL-6. The extract must specifically be erinacine-standardized — this is a real distinction, not a technicality. Erinacines (from Lion's Mane mycelium) inhibit IκBα phosphorylation and activate Nrf2/HO-1 in microglial cell models with direct supporting data; hericenones (the fruiting-body compounds most "Lion's Mane" supplements are actually standardized to) don't carry the same confirmed evidence for this specific mechanism. Check the label for erinacine content, not just "Hericium erinaceus."

Not every intervention needs to cross the BBB. The vagus nerve carries a cholinergic anti-inflammatory pathway — vagal efferent signaling → acetylcholine → α7 nicotinic receptor — and microglia carry that receptor themselves, so activation can push them toward a neuroprotective phenotype without the signaling molecule ever entering brain tissue. The causal evidence for the route itself is strong: Bravo et al. 2011 (PNAS) showed a probiotic's effect on mouse brain chemistry and behavior disappeared completely after surgical vagotomy — that's a causal severing, not a correlation. The strongest plant-based candidate, and the only one with human data, is hop bitter acids (Humulus lupulus): bitter-taste receptors along the GI tract signal to vagal afferents via cholecystokinin release, and a randomized human crossover trial measured a real heart-rate-variability change after a single dose. This entire route depends on a working gut-vagal signaling chain — a fiber-poor diet undermines it before the botanicals get a chance to work: dietary fiber → short-chain fatty acids (via microbiome fermentation) → direct activation of FFAR2/FFAR3 receptors on vagal afferents, with the same fatty acids also suppressing microglial inflammation directly. Curcumin may work as a second route here too — a hypothesized positive allosteric modulator of α7nAChR — but that's explicitly unconfirmed, not a claimed mechanism.

Huperzine A (Huperzia serrata) is the strongest single new candidate found in this rebuild — BBB penetration confirmed as better than donepezil, tacrine, or rivastigmine on penetration, bioavailability, and duration of action, with a 20-trial meta-analysis (n=1,823) showing significant cognitive/ADL improvement. It's included as optional, not baseline, for a specific reason: it works via acetylcholinesterase inhibition — the same mechanism class as donepezil — so combining it with a prescribed cholinesterase inhibitor is a real interaction risk, not a theoretical one. It's also worth naming plainly that almost the entire trial base is Chinese, carries documented high risk-of-bias, and an older Cochrane review called the evidence "insufficient" — a more cautious read than the meta-analysis alone suggests.

Every compound in Steps 2–6 still needs a functioning delivery and clearance system to reach where it's supposed to work. The FINGER trial (Ngandu et al., Lancet 2015, n=1,260) is the strongest evidence in this entire protocol that this layer matters as much as any single compound: a 2-year multidomain lifestyle intervention — exercise, diet, cognitive training, vascular risk monitoring — produced 25% greater cognitive improvement than standard advice, with the benefit still measurable in high-adherence participants at 11 years (Ngandu et al., Alzheimer's & Dementia, 2025). Replicated in the US (POINTER, JAMA 2025, n=2,111) and across 11 Latin American countries (LatAm-FINGERS, 2026) — not a one-off finding.

Two elements from that stack tie directly to this protocol's own mechanisms. First: aerobic exercise is a documented glymphatic pump, not a generic health tip — a 2025 Nature Communications imaging study measured increased putative glymphatic influx and meningeal lymphatic flow after 12 weeks of structured cycling, the same clearance system Step 1 depends on. A separate randomized crossover trial in sedentary older men found a 27% increase in frontal-lobe cerebral blood flow after aerobic training, matched by improved executive function. Second: blood pressure is the single most actionable vascular lever tested — the SPRINT MIND trial found intensive control (systolic target <120mmHg) reduced risk of mild cognitive impairment compared to standard control (<140mmHg), though the ideal target for the oldest-old (85+) remains unresolved.

This step is graded on a different evidence standard than Steps 2–6 deliberately: exercise and blood pressure don't need to cross the blood-brain barrier to work — they act on the vasculature and cerebrospinal fluid dynamics that deliver and clear everything else. It belongs at the foundation alongside Step 1, not as an afterthought; it's placed last here only to avoid renumbering the existing step IDs.